Pulling SEC filings + quote and writing the call…
Pulling SEC filings + quote and writing the call…

Medpace Holdings, Inc.
Next earnings Jul 22, 2026 (after close) · consensus $4.05 EPS, $704M rev
Last earnings -1.3% on 2026-04-22
Debt-free CRO compounding revenue +20% with 98.3% ROE and aggressive buybacks, at a reasonable 30x P/E.
Sources: SEC EDGAR (CIK 0001668397, latest 10-Q filed 2026-04-23) · EODHD · analysis by claude-code · as of 6/21/2026, 8:45:38 PM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.
Solid fundamentals at a roughly fair price — reasonable risk/reward at today's level.
Medpace is a high-quality compounder. FY2025 revenue grew 20.0% to $2.53B, extending a remarkably consistent ramp from $1.14B in FY2021 through $1.46B, $1.89B, $2.11B, and now $2.53B. Management attributes the $421.2 million increase to strong activity in Metabolic, Oncology and Central Nervous System therapeutic areas. Profitability is excellent: operating income of $535M (+19.7%), a 21.1% operating margin, net income of $451M (+11.6%), and diluted EPS of $15.28 (+21.0%). The CRO model converts to cash superbly, with operating cash flow of $713M (+17.1%) against just $31.4M of capex.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $1.14B | $1.46B | $1.89B | $2.11B | $2.53B |
| Gross profit | — | — | — | — | — |
| Operating income | $199M | $279M | $337M | $447M | $535M |
| Net income | $182M | $245M | $283M | $404M | $451M |
| Diluted EPS | $4.81 | $7.28 | $8.88 | $12.63 | $15.28 |
| Net margin | 15.9% | 16.8% | 15.0% | 19.2% | 17.8% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
3 buys · 2 sells · 2 members · last 180d
Self-reported periodic transaction reports (STOCK Act). Amounts are disclosed ranges; a trade may be a spouse's. Disclosures lag the trade by up to ~45 days. Source: House Clerk + Senate eFD.
1482 tracked peers · median
Last 90 days: 0 open-market buys · 1 sale
| 2026-05-28 | EWALD STEPHEN P General Counsel & Corp. Secy. | Exercise | 16.3K @ $138.87 | $2.27M |
| 2026-05-28 | EWALD STEPHEN P General Counsel & Corp. Secy. | Sell | 16.3K @ $450.00 | $7.36M |
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.